Onelar (Duloxetine)

Duloxetine, the active ingredient in Onelar, is a serotonin‑norepinephrine reuptake inhibitor (SNRI) presented as a strength/form for oral use. It is prescribed for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain in adults.

GNH USA supplies Onelar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Duloxetine acts on central nervous system pathways that regulate mood and pain perception. - Major depressive disorder: alleviates depressive symptoms and improves functional capacity. - Generalized anxiety disorder: reduces anxiety levels and associated physical symptoms. - Diabetic peripheral neuropathic pain: lessens pain intensity and improves quality of life. - Fibromyalgia: decreases widespread musculoskeletal pain and fatigue. - Chronic musculoskeletal pain: provides relief from chronic low‑back and osteoarthritis pain.

Adverse reactions to duloxetine vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dry mouth: reduced salivation. - Headache: intermittent cranial pain. - Sweating: increased perspiration. - Fatigue: feeling of tiredness. - Dizziness: light‑headed sensations.

Serious or Rare Side Effects: - Hepatotoxicity: signs of liver injury such as jaundice. - Hyponatremia: low blood sodium presenting with confusion or seizures. - Serotonin syndrome: agitation, hyperthermia, and neuromuscular abnormalities. - Severe hypertension: markedly elevated blood pressure. - Suicidal thoughts: emergence of suicidal ideation, especially early in treatment. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating duloxetine, clinicians should evaluate patient history and monitor for specific risks. - Hepatic function: assess liver enzymes in patients with liver disease. - Renal function: adjust monitoring in severe renal impairment. - Cardiovascular status: watch for hypertension or tachycardia. - Psychiatric monitoring: observe for worsening depression or emergent suicidal thoughts. - Drug‑interaction review: avoid concomitant use with MAO inhibitors and serotonergic agents. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Duloxetine may interact with several medication classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Strong CYP1A2 inhibitors (e.g., fluvoxamine): may increase duloxetine plasma levels. - Serotonergic opioids (e.g., tramadol): heightened serotonin toxicity.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., metoprolol): possible altered metabolism. - NSAIDs: increased risk of gastrointestinal bleeding. - Anticoagulants (e.g., warfarin): potential for enhanced anticoagulant effect.